ALNY vs. VEEV: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ALNY and VEEV, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ALNY’s market capitalization stands at 43.28 billion USD, while VEEV’s is 46.46 billion USD, indicating their market valuations are broadly comparable.
VEEV carries a higher beta at 0.99, indicating it’s more sensitive to market moves, while ALNY (beta: 0.21) exhibits greater stability.
| Symbol | ALNY | VEEV |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | Veeva Systems Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Healthcare Information Services |
| CEO | Yvonne L. Greenstreet | Peter P. Gassner |
| Price | 331.91 USD | 284.29 USD |
| Market Cap | 43.28 billion USD | 46.46 billion USD |
| Beta | 0.21 | 0.99 |
| Exchange | NASDAQ | NYSE |
| IPO Date | June 1, 2004 | October 16, 2013 |
| ADR | No | No |
Historical Performance
This chart compares the performance of ALNY and VEEV by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ALNY
-509.33%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
ALNY has a negative Return on Equity of -509.33%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
VEEV
13.74%
Medical - Healthcare Information Services Industry
- Max
- 25.87%
- Q3
- 8.12%
- Median
- 2.99%
- Q1
- -18.32%
- Min
- -48.18%
In the upper quartile for the Medical - Healthcare Information Services industry, VEEV’s Return on Equity of 13.74% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Return on Invested Capital
ALNY
-2.79%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
ALNY has a negative Return on Invested Capital of -2.79%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
VEEV
9.39%
Medical - Healthcare Information Services Industry
- Max
- 26.81%
- Q3
- 8.81%
- Median
- 2.09%
- Q1
- -11.56%
- Min
- -32.60%
In the upper quartile for the Medical - Healthcare Information Services industry, VEEV’s Return on Invested Capital of 9.39% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
ALNY
-11.49%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
ALNY has a negative Net Profit Margin of -11.49%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
VEEV
27.34%
Medical - Healthcare Information Services Industry
- Max
- 39.13%
- Q3
- 9.34%
- Median
- 1.37%
- Q1
- -15.05%
- Min
- -39.66%
A Net Profit Margin of 27.34% places VEEV in the upper quartile for the Medical - Healthcare Information Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
ALNY
-4.91%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
ALNY has a negative Operating Profit Margin of -4.91%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
VEEV
26.97%
Medical - Healthcare Information Services Industry
- Max
- 39.94%
- Q3
- 11.27%
- Median
- 3.94%
- Q1
- -9.81%
- Min
- -29.30%
An Operating Profit Margin of 26.97% places VEEV in the upper quartile for the Medical - Healthcare Information Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ALNY | VEEV |
|---|---|---|
| Return on Equity (TTM) | -509.33% | 13.74% |
| Return on Assets (TTM) | -6.40% | 10.05% |
| Return on Invested Capital (TTM) | -2.79% | 9.39% |
| Net Profit Margin (TTM) | -11.49% | 27.34% |
| Operating Profit Margin (TTM) | -4.91% | 26.97% |
| Gross Profit Margin (TTM) | 86.01% | 75.50% |
Financial Strength
Current Ratio
ALNY
3.04
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
ALNY’s Current Ratio of 3.04 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
VEEV
4.60
Medical - Healthcare Information Services Industry
- Max
- 5.37
- Q3
- 3.30
- Median
- 1.91
- Q1
- 1.37
- Min
- 0.54
VEEV’s Current Ratio of 4.60 is in the upper quartile for the Medical - Healthcare Information Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio
ALNY
11.28
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
With a Debt-to-Equity Ratio of 11.28, ALNY operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
VEEV
0.01
Medical - Healthcare Information Services Industry
- Max
- 1.14
- Q3
- 0.65
- Median
- 0.16
- Q1
- 0.04
- Min
- 0.00
Falling into the lower quartile for the Medical - Healthcare Information Services industry, VEEV’s Debt-to-Equity Ratio of 0.01 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio
ALNY
-0.79
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
ALNY has a negative Interest Coverage Ratio of -0.79. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
VEEV
--
Medical - Healthcare Information Services Industry
- Max
- 12.12
- Q3
- 3.11
- Median
- 1.20
- Q1
- -12.03
- Min
- -25.76
Interest Coverage Ratio data for VEEV is currently unavailable.
Financial Strength at a Glance
| Symbol | ALNY | VEEV |
|---|---|---|
| Current Ratio (TTM) | 3.04 | 4.60 |
| Quick Ratio (TTM) | 2.98 | 4.60 |
| Debt-to-Equity Ratio (TTM) | 11.28 | 0.01 |
| Debt-to-Asset Ratio (TTM) | 0.31 | 0.01 |
| Net Debt-to-EBITDA Ratio (TTM) | -1.85 | -2.39 |
| Interest Coverage Ratio (TTM) | -0.79 | -- |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ALNY and VEEV. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
VEEV
0.00%
Medical - Healthcare Information Services Industry
- Max
- 7.19%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VEEV currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
VEEV
0.00%
Medical - Healthcare Information Services Industry
- Max
- 130.89%
- Q3
- 2.61%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VEEV has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ALNY | VEEV |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio
ALNY
-159.59
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
ALNY has a negative P/E Ratio of -159.59. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
VEEV
59.27
Medical - Healthcare Information Services Industry
- Max
- 114.57
- Q3
- 67.12
- Median
- 45.42
- Q1
- 28.19
- Min
- 6.48
VEEV’s P/E Ratio of 59.27 is within the middle range for the Medical - Healthcare Information Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
ALNY
-43.29
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
ALNY has a negative Forward PEG Ratio of -43.29. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
VEEV
4.64
Medical - Healthcare Information Services Industry
- Max
- 6.35
- Q3
- 2.93
- Median
- 2.00
- Q1
- 0.55
- Min
- 0.03
A Forward PEG Ratio of 4.64 places VEEV in the upper quartile for the Medical - Healthcare Information Services industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
Price-to-Sales Ratio
ALNY
18.43
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
ALNY’s P/S Ratio of 18.43 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
VEEV
16.27
Medical - Healthcare Information Services Industry
- Max
- 10.90
- Q3
- 5.95
- Median
- 2.46
- Q1
- 1.42
- Min
- 0.36
With a P/S Ratio of 16.27, VEEV trades at a valuation that eclipses even the highest in the Medical - Healthcare Information Services industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio
ALNY
372.86
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
VEEV
7.45
Medical - Healthcare Information Services Industry
- Max
- 12.91
- Q3
- 6.69
- Median
- 2.84
- Q1
- 1.88
- Min
- 1.03
The P/B Ratio is often not a primary valuation metric for the Medical - Healthcare Information Services industry.
Valuation at a Glance
| Symbol | ALNY | VEEV |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -159.59 | 59.27 |
| Forward PEG Ratio (TTM) | -43.29 | 4.64 |
| Price-to-Sales Ratio (P/S, TTM) | 18.43 | 16.27 |
| Price-to-Book Ratio (P/B, TTM) | 372.86 | 7.45 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -574.08 | 38.59 |
| EV-to-EBITDA (TTM) | -285.32 | 56.35 |
| EV-to-Sales (TTM) | 18.55 | 15.61 |